Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma.

Zhou J, Roh JW, Bandyopadhyay S, Chen Z, Munkarah AR, Hussein Y, Alosh B, Jazaerly T, Hayek K, Semaan A, Sood AK, Ali-Fehmi R.

Gynecol Oncol. 2013 Feb;128(2):344-8. doi: 10.1016/j.ygyno.2012.07.128. Epub 2012 Aug 4.

PMID:
22871469
2.

Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.

Eskander RN, Ji T, Huynh B, Wardeh R, Randall LM, Hoang B.

Int J Gynecol Cancer. 2013 Jul;23(6):997-1005. doi: 10.1097/IGC.0b013e318296a265.

3.

[Expression and relationship of Ezh2, Runx3 and caspase-3 in endometrial adenocarcinoma].

Guo ZL, Chen K, Wang XQ, Hu W.

Zhonghua Bing Li Xue Za Zhi. 2011 Jun;40(6):387-91. Chinese.

PMID:
21914347
4.

EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.

Guo S, Li X, Rohr J, Wang Y, Ma S, Chen P, Wang Z.

Diagn Pathol. 2016 Apr 26;11:41. doi: 10.1186/s13000-016-0491-5.

5.

Focal adhesion kinase overexpression and its impact on human osteosarcoma.

Ren K, Lu X, Yao N, Chen Y, Yang A, Chen H, Zhang J, Wu S, Shi X, Wang C, Sun X.

Oncotarget. 2015 Oct 13;6(31):31085-103. doi: 10.18632/oncotarget.5044.

6.

EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.

Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF, Liao YJ, Deng HX, Chen YC, Guan XY, Zeng YX, Kung HF, Xie D.

Carcinogenesis. 2010 Sep;31(9):1576-83. doi: 10.1093/carcin/bgq150. Epub 2010 Jul 28.

PMID:
20668008
7.

Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma.

Liu DC, Yang ZL.

Pathol Res Pract. 2011 Aug 15;207(8):472-8. doi: 10.1016/j.prp.2011.05.010. Epub 2011 Jun 29.

PMID:
21719208
8.

Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder.

Wang H, Albadine R, Magheli A, Guzzo TJ, Ball MW, Hinz S, Schoenberg MP, Netto GJ, Gonzalgo ML.

Urol Oncol. 2012 Jul-Aug;30(4):428-33. doi: 10.1016/j.urolonc.2010.09.005. Epub 2011 Mar 10.

PMID:
21396836
9.

Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.

Lee H, Yoon SO, Jeong WY, Kim HK, Kim A, Kim BH.

Hum Pathol. 2012 Oct;43(10):1704-10. doi: 10.1016/j.humpath.2011.12.019. Epub 2012 Apr 18.

PMID:
22520951
10.

Increased EZH2 expression is associated with proliferation and progression of cervical cancer and indicates a poor prognosis.

Liu Y, Liu T, Bao X, He M, Li L, Yang X.

Int J Gynecol Pathol. 2014 May;33(3):218-24. doi: 10.1097/PGP.0b013e31829c6574.

PMID:
24681730
11.

Expression and clinical significance of FAK and Src proteins in human endometrial adenocarcinoma.

Chatzizacharias NA, Giaginis C, Gatzidou E, Tsourouflis G, Sfiniadakis I, Alexandrou P, Theocharis SE.

Pathol Oncol Res. 2011 Jun;17(2):277-85. doi: 10.1007/s12253-010-9310-6. Epub 2010 Nov 7.

PMID:
21058027
12.

Focal adhesion kinase overexpression in endometrial neoplasia.

Livasy CA, Moore D, Cance WG, Lininger RA.

Appl Immunohistochem Mol Morphol. 2004 Dec;12(4):342-5.

PMID:
15536334
13.

Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study.

Gabriel B, Hasenburg A, Waizenegger M, Orlowska-Volk M, Stickeler E, zur Hausen A.

Int J Gynecol Cancer. 2009 Oct;19(7):1221-5. doi: 10.1111/IGC.0b013e3181b33c61.

PMID:
19823058
14.

Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.

Xu C, Hao K, Hu H, Sheng Z, Yan J, Wang Q, Yu L.

Lung Cancer. 2014 Nov;86(2):268-73. doi: 10.1016/j.lungcan.2014.09.010. Epub 2014 Sep 22.

PMID:
25262426
15.

Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer.

Dong M, Fan XJ, Chen ZH, Wang TT, Li X, Chen J, Lin Q, Wen JY, Ma XK, Wei L, Ruan DY, Lin ZX, Liu Q, Wu XY, Wan XB.

Oncol Rep. 2014 Sep;32(3):1101-7. doi: 10.3892/or.2014.3322. Epub 2014 Jul 10.

PMID:
25017254
16.

Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma.

Hayashi A, Morikawa T, Kawai T, Kume H, Ishikawa S, Homma Y, Fukayama M.

Virchows Arch. 2014 Apr;464(4):463-71. doi: 10.1007/s00428-014-1541-6. Epub 2014 Jan 21.

PMID:
24446035
17.

Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct.

Sasaki M, Matsubara T, Yoneda N, Nomoto K, Tsuneyama K, Sato Y, Nakanuma Y.

Histopathology. 2013 Feb;62(3):446-57. doi: 10.1111/his.12016. Epub 2012 Nov 16.

PMID:
23163606
18.

Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.

Shiogama S, Yoshiba S, Soga D, Motohashi H, Shintani S.

Anticancer Res. 2013 Oct;33(10):4309-17.

PMID:
24122997
19.

Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.

Alford SH, Toy K, Merajver SD, Kleer CG.

Breast Cancer Res Treat. 2012 Apr;132(2):429-37. doi: 10.1007/s10549-011-1591-2. Epub 2011 May 26.

20.

Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma.

Jia N, Li Q, Tao X, Wang J, Hua K, Feng W.

Oncol Lett. 2014 Nov;8(5):2049-2054. Epub 2014 Aug 12.

Supplemental Content

Support Center